CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biotechnology company founded in 1998 and headquartered in Menlo Park, California. The company went public in 2004 and has evolved from a research-stage enterprise into a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for severe metabolic, oncologic, and neuropsychiatric disorders. Corcept's breakthrough lies in its expertise with <b>cortisol modulation</b>, a novel therapeutic approach that targets the harmful effects of excess cortisol in various disease states. The company has successfully commercialized its first drug, Korlym, and has built a robust pipeline of cortisol modulators targeting multiple therapeutic areas.